OBJECTIVE: X-linked adrenoleukodystrophy (ALD) is a neurodegenerative disorder due to mutations in the peroxisomal very long-chain fatty acyl-CoA transporter, ABCD1, with limited therapeutic options. ALD may manifest in a slowly progressive adrenomyeloneuropathy (AMN) phenotype, or switch to rapid inflammatory demyelinating cerebral disease (cALD), in which microglia have been shown to play a pathophysiological role. The aim of this study was to determine the role of patient phenotype in the immune response of ex vivo monophagocytic cells to stimulation, and to evaluate the efficacy of polyamidoamine dendrimer conjugated to the antioxidant precursor N-acetyl-cysteine (NAC) in modulating this immune response. METHODS: Human monophagocytic cells were derived from fresh whole blood, from healthy (n = 4), heterozygote carrier (n = 4), AMN (n = 7), and cALD (n = 4) patients. Cells were exposed to very long-chain fatty acids (VLCFAs; C24:0 and C26:0) and treated with dendrimer-NAC (D-NAC). RESULTS: Ex vivo exposure to VLCFAs significantly increased tumor necrosis factor α (TNFα) and glutamate secretion from cALD patient macrophages. Additionally, a significant reduction in total intracellular glutathione was observed in cALD patient cells. D-NAC treatment dose-dependently reduced TNFα and glutamate secretion and replenished total intracellular glutathione levels in cALD patient macrophages, more efficiently than NAC. Similarly, D-NAC treatment decreased glutamate secretion in AMN patient cells. INTERPRETATION: ALD phenotypes display unique inflammatory profiles in response to VLCFA stimulation, and therefore ex vivo monophagocytic cells may provide a novel test bed for therapeutic agents. Based on our findings, D-NAC may be a viable therapeutic strategy for the treatment of cALD. Ann Neurol 2018;84:452-462.
OBJECTIVE:X-linked adrenoleukodystrophy (ALD) is a neurodegenerative disorder due to mutations in the peroxisomal very long-chain fatty acyl-CoA transporter, ABCD1, with limited therapeutic options. ALD may manifest in a slowly progressive adrenomyeloneuropathy (AMN) phenotype, or switch to rapid inflammatory demyelinating cerebral disease (cALD), in which microglia have been shown to play a pathophysiological role. The aim of this study was to determine the role of patient phenotype in the immune response of ex vivo monophagocytic cells to stimulation, and to evaluate the efficacy of polyamidoamine dendrimer conjugated to the antioxidant precursor N-acetyl-cysteine (NAC) in modulating this immune response. METHODS:Human monophagocytic cells were derived from fresh whole blood, from healthy (n = 4), heterozygote carrier (n = 4), AMN (n = 7), and cALD (n = 4) patients. Cells were exposed to very long-chain fatty acids (VLCFAs; C24:0 and C26:0) and treated with dendrimer-NAC (D-NAC). RESULTS: Ex vivo exposure to VLCFAs significantly increased tumor necrosis factor α (TNFα) and glutamate secretion from cALD patient macrophages. Additionally, a significant reduction in total intracellular glutathione was observed in cALD patient cells. D-NAC treatment dose-dependently reduced TNFα and glutamate secretion and replenished total intracellular glutathione levels in cALD patient macrophages, more efficiently than NAC. Similarly, D-NAC treatment decreased glutamate secretion in AMNpatient cells. INTERPRETATION:ALD phenotypes display unique inflammatory profiles in response to VLCFA stimulation, and therefore ex vivo monophagocytic cells may provide a novel test bed for therapeutic agents. Based on our findings, D-NAC may be a viable therapeutic strategy for the treatment of cALD. Ann Neurol 2018;84:452-462.
Authors: Elizabeth Nance; Michael Porambo; Fan Zhang; Manoj K Mishra; Markus Buelow; Rachel Getzenberg; Michael Johnston; Rangaramanujam M Kannan; Ali Fatemi; Sujatha Kannan Journal: J Control Release Date: 2015-07-13 Impact factor: 9.776
Authors: Malu-Clair van de Beek; Rob Ofman; Inge Dijkstra; Frits Wijburg; Marc Engelen; Ronald Wanders; Stephan Kemp Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-06-27 Impact factor: 5.187
Authors: Bela R Turk; Benjamin E Theisen; Christina L Nemeth; Joel S Marx; Xiaohai Shi; Melissa Rosen; Richard O Jones; Ann B Moser; Paul A Watkins; Gerald V Raymond; Carol Tiffany; Ali Fatemi Journal: JAMA Neurol Date: 2017-05-01 Impact factor: 18.302
Authors: Ann B Moser; Yanqiu Liu; Xiaohai Shi; Ulrike Schrifl; Shandi Hiebler; Ali Fatemi; Nancy E Braverman; Steven J Steinberg; Paul A Watkins Journal: J Cell Biochem Date: 2021-05-30 Impact factor: 4.480
Authors: Yang Liu; Quan Na; Jin Liu; Anguo Liu; Akosua Oppong; Ji Yeon Lee; Anna Chudnovets; Jun Lei; Rishi Sharma; Sujatha Kannan; Rangaramanujam M Kannan; Irina Burd Journal: Front Bioeng Biotechnol Date: 2022-01-28
Authors: Christina L Nemeth; Özgül Gӧk; Sophia N Tomlinson; Anjali Sharma; Ann B Moser; Sujatha Kannan; Rangaramanujam M Kannan; Ali Fatemi Journal: Neurotherapeutics Date: 2022-10-07 Impact factor: 6.088
Authors: Elizabeth Smith Khoury; Anjali Sharma; Rajasekhar R Ramireddy; Ajit G Thomas; Jesse Alt; Amanda Fowler; Rana Rais; Takashi Tsukamoto; Mary E Blue; Barbara Slusher; Sujatha Kannan; Rangaramanujam M Kannan Journal: Theranostics Date: 2020-04-27 Impact factor: 11.556